{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4PGc7pIJDA","lastupdate":"2023-10-01T00:00:00.000Z","update_date":"2023-10-01T00:00:00.000Z","lastModified":"Aug 31, 2024","active":1,"confidence_score":89,"confidence_score_reason":"video or image, markets, not claimed","urlname":"elgan-pharma","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$XqBs0ol42LtrlcKm6w8kcc6yIB5l5FIAfbSch3vjeEfTLmEWm0gqNL","name":"ELGAN Pharma","oneliner":"Neonatal Therapies","registrar":"515843720","website":"https://elganpharma.com","careerspage":"","founded_month":5,"founded_year":2018,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/67923556","instagram":""},"social":["https://www.linkedin.com/company/67923556"],"flattenedsociallinks":"https://www.linkedin.com/company/67923556","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":25,"patent":1,"raised":7500000,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["ELGANPharma"],"about":"ELGAN Pharma is a clinical-stage neonatology-focused biotechnology company developing safe, tailored therapies to address medical problems and developmental difficulties common in babies born very early.\n\nThe company has two leading clinical programs: ELGN-GI and ELGN-EYE. Both therapies address high unmet medical needs of preterm infants with no existing solutions to date.\n\nELGN-GI promotes a faster maturation of an infant’s intestines, allowing them to rapidly reach full enteral feeding and become independent from parenteral nutrition while minimizing serious complications and reducing burden and costs to healthcare systems. The product has completed several clinical trials, including a successful phase 3, and is currently starting a second phase 2.\n\nELGN-EYE is a local drug targeted at preventing vision impairment due to retinopathy of prematurity (ROP), a condition caused by the underdeveloped blood vessels in the eyes of premature babies at the time of birth. ROP is the leading cause of blindness in children worldwide. A phase 1 study of the product was successfully concluded and a phase 2 is currently launching.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97246098600","country":null,"address":{"israeli":[{"id":"1351b578-1464-4855-947f-3694b141e867","city":"Nazareth","type":null,"address":"Wadi el-Haj Street 13, Nazareth, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"North District","news":[{"id":"CwydWcSNybRUIPsF6USBXNBryc5mXJNKHpVWhIZQl4lB0nMNiXNTkp","date":"Jun 5, 2025","link":"https://www.prnewswire.com/il/news-releases/elgan-pharma-and-chiesi-group-announce-first-participating-infants-dosed-in-phase-3-study-of-elgn-2112-for-treatment-of-intestinal-malabsorption-in-preterm-infants-302474218.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"Elgan Pharma","layoffs":null,"summary":"Elgan Pharma and Chiesi Farmaceutici S.p.A have announced the commencement of a Phase 3 clinical trial for ELGN-2112, a novel treatment for intestinal malabsorption in preterm infants. This collaboration aims to address the unique medical needs of premature infants by improving gastrointestinal function and reducing the need for intravenous feeding. The FIT-PIV study will enroll 420 infants across multiple international sites, focusing on achieving full enteral feeding earlier to reduce complications. The partnership highlights both companies commitment to advancing neonatal care through innovative therapeutic solutions.","partners":"Chiesi Farmaceutici S.p.A","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["neonatology","clinical trial","intestinal malabsorption","preterm infants","ELGN-2112"],"date_of_event":"not specified","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Ac5eB3j9H1taAn7ZezT5RCgnN3GIOAiKTRUD1LAZMyP4wcVMXFYmRB","news_summary":"/PRNewswire/ -- Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A today announced the dosing of the first participating infants in FIT-PIV, a Phase 3 clinical...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hfbqCzEKUtJGbn3GbHiM5lLBuB8kRx6P3XumR0qk1o5aJe64HhtESh","date":"Jul 19, 2023","link":"https://nocamels.com/2023/07/startup-treating-newborns-in-serious-condition-raises-2-5m/","source":"nocamels.com","visible":1,"analysis":{"tags":"Grant, Biopharma, Treatment","company":"ELGAN Pharma","layoffs":"Not mentioned","summary":"Israeli biopharma company, ELGAN Pharma, has been awarded a $2.5 million grant by the European Innovation Council (EIC). The company is developing an oral formula for the treatment of intestinal malabsorption, a digestive disorder that prevents preterm infants from absorbing nutrients from feeding. The grant will help ELGAN embark on a clinical study to further prove the safety and efficacy of its treatment. ELGAN Pharma was founded in 2018, and is based in Nazareth, northern Israel.","partners":"Not mentioned","customers":"Not mentioned","investors":"European Innovation Council (EIC)","confidence":9,"key_topics":["Grant","Treatment","Infants","Clinical Study","Biopharma"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$2.5 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7wDGlPFdL8BdgNQcJVkDbEf19jbUxQUdfgZQ0zGkewwX6a3AjTy8Sx","news_summary":"Startup Treating Newborns In Serious Condition Raises $2.5M","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"rEMkLlE4qG8Q7RfBsjwsLAESS1ZfCA0oRMFIApHMP8GMx2hM7tFy7B","date":"Mar 2, 2022","link":"https://www.prnewswire.com/news-releases/elgan-pharma-announces-positive-results-from-its-phase-iii-study-of-elgn-gi-in-preterm-infants-for-treatment-of-intestinal-malabsorption-301493745.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"Elgan Pharma","layoffs":null,"summary":"Elgan Pharma, a clinical biopharmaceutical company, announced positive results from a Phase III study of their proprietary enteral insulin formulation, ELGN-GI, for the treatment of intestinal malabsorption in preterm infants. The study showed significant improvements in gastrointestinal function and a reduction in related complications. The company plans to initiate a second Phase III trial for ELGN-GI later in 2022. Elgan Pharma also mentioned their plans to launch a Phase IIb clinical trial for their second product candidate, ELGN-EYE, for the treatment of retinopathy of prematurity. The company aims to develop therapies for the unmet medical needs of premature infants. The Phase III study enrolled 303 infants across multiple sites. No specific partners or customers were mentioned in the article.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["ELGN-GI","preterm infants","intestinal malabsorption","Phase III study","clinical benefits"],"date_of_event":"2022-03-02","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"l8ffKth7qRYjpic6l8694bSosnUTKpuQSCT5hgk7KtH0BRCMO84E4m","news_summary":"Elgan Pharma Announces Positive Results from its Phase III Study of ELGN-GI in Preterm Infants for Treatment of Intestinal Malabsorption","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"93909b3f-2804-426b-aab8-86fbc2670429","date":"Mar 2, 2022","link":"https://www.jpost.com/health-and-wellness/pregnancy-and-birth/article-699123","source":"www.jpost.com","visible":1,"analysis":{"tags":"biopharmaceutical, infant health","company":"Elgan Pharma","layoffs":null,"summary":"Elgan Pharma has announced the success of its ELGN-GI insulin formulation in improving the early lives of premature babies. The formulation, tailored for newborns, helps infants with feeding intolerance caused by intestinal malabsorption. It improves gastrointestinal function, reduces complications, and decreases the need for intravenous feeding. The use of ELGN-GI led to significant improvements in gastrointestinal function and a decrease in hospital stay. Elgan Pharma plans to initiate a second Phase III trial for ELGN-GI in 2022. The company is also working on a treatment for retinopathy of prematurity. The success of ELGN-GI positions Elgan Pharma as a pioneer in developing therapies for the unique medical needs of premature infants.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["ELGN-GI insulin formulation","preterm infants","gastrointestinal function","feeding intolerance","clinical trials"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NRs1Oqo6mOsUY1GX0TvsbrDzFX4bkm6G9CssqbevYfefcrExmGLM3J","news_summary":"https://www.jpost.com/health-and-wellness/pregnancy-and-birth/article-699123","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"k3I2IsTPTi9Y6k2ASrHpDavp4AtdF6XN3fkn6xDh5DFTEu3tg9AY7I","date":"May 6, 2021","link":"https://isotopia-global.com/elgan-pharma-and-isotopia-molecular-imaging-signed-strategic-agreement/","source":"isotopia-global.com","visible":1,"analysis":{"tags":"partnership","company":"Isotopia","layoffs":null,"summary":"Isotopia and Elgan Pharma have entered into a partnership agreement. Isotopias capabilities in sterile production and compliance with good manufacturing practices (cGMP) will support Elgans transition to GMP production for Phase III and commercial scale. Isotopia will provide resources for successful clinical trials and marketing authorization application (MAA) filing. Isotopia is a collaboration between The Metrontario Group and Israeli scientists in the field of radiopharmaceuticals and sterile manufacturing. Elgan Pharma is a biotechnology company focused on neonatology, developing therapies for premature infants. The partnership aims to deliver breakthrough therapies to premature infants and improve outcomes for Extremely Low Gestational Age Newborns (ELGANs).","partners":["Elgan Pharma"],"customers":null,"investors":null,"confidence":8,"key_topics":["Isotopia","Elgan","partnership","GMP production","clinical trials"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HMAXS4w7Y81qQnw6X19t2TlGVShpR8qapTzuKutjid9KpTwps5Mcn3","news_summary":"Elgan Pharma& Isotopia Molecular Imaging Signed a Strategic agreement","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":5,"techcommunityinvolvement":null,"mediagallery":[],"tags":["biopharmaceutical","visually-impaired","biotechnology","nanotechnology","medical-technologies","treatments","eye-diseases"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1upgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If81MwLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["ELGN-EYE","ELGN-GI"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$2.5M","totalrounds":3,"fundingstage":"A","totalfunding":"$7.5M","publicinvestors":2,"lastpublicfunding":2500000,"totalpublicrounds":3,"totalpublicfunding":7500000},"team":[{"name":"Miki Olshansky","email":"miki@elganpharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NGskpYKDA","bounced":false,"claimed":0,"founder":1,"urlname":"miki-olshansky","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgsYTGmQkM","position":"Co-founder & CEO","last_name":"Olshansky","claimtoken":"RryKRJY2U2MNOB0GXsBTGC4eUteA9U0zYbHzcwLu6qU7yJe90gb9AK","first_name":"Miki","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/miki-olshansky-24644/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-23 18:55:44.000000","initials":"MO","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Stav Zeldis","email":"stav@elganpharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Ij6otQJDA","bounced":false,"claimed":0,"founder":1,"urlname":"stav-zeldis","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgsZPXlwoM","position":"Co-founder & VP Regulatory Affairs","last_name":"Zeldis","claimtoken":"e4CLLovMrG0SHOLe3Ye3jDM2pApYrYI65MNjbjAYdlkz76zcn5O800","first_name":"Stav","picturekey":"$jsx8jgc8rVU84xOGFzYJwBadZnXRwM0IPVQcr8r4DLGLnmK3TY3HYW","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/stav-zeldis-449a99b6/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-23 18:55:48.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$jsx8jgc8rVU84xOGFzYJwBadZnXRwM0IPVQcr8r4DLGLnmK3TY3HYW","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Tali  Schaffer","email":"tali@elganpharma.com","phone":"","gender":"Female","userid":"Nq5GCEb7tQa5YIKWU5dbF1LwUM2qIqEGkWrGNbXiDlBtJ1sQZhOzgE","bounced":false,"claimed":null,"founder":0,"urlname":"tali-schaffer","visible":1,"memberid":"3tWRI3JxcCyQsAsZWMsyi17693wutK2g2KvhL7Wq7dpPeZ5vC5vSK8","position":"Executive Director Clinical Affairs","last_name":"Schaffer","claimtoken":"wX51JRfFiL9JAxGsmgoTtrbMXvnxdAcOYUfHRyp0rCDWXiJAcTcsKT","first_name":"Tali ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/talischaf/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-12-23 18:58:48.000000","initials":"TS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2020-07-21T00:00:00.000Z","crunchbaseid":"","lastupdator":"Matan Eblagon","lastupdator_email":"matane@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2020-07-20T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"EiKfAeJyt6OIesxPNxXVkgatvJTMsC10edc9DOb7qDnhL8uyO5itQK","date":"Jul 2023","amount":"$2.5M","source":"https://nocamels.com/2023/07/startup-treating-newborns-in-serious-condition-raises-2-5m/","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"EIC Accelerator","type":"Accelerator","amount":null,"hidden":true,"country":"Belgium","fullurl":"/program_page/eic-accelerator","logokey":null,"tagline":"EIC Accelerator is an accelerator managed by the European Innovation Council and European Commission (EC) based in Brussels, Belgium. The firm seeks to support small and medium enterprises.","urlname":"/program_page/eic-accelerator","isisraeli":0,"investorid":"DSnozIu4tFaENytWcT1Y4Wzro134ttf9vwbDP23n82MplEWezRgvpQ","fundingtype":"General","leadpartner":null,"investmentid":"PZpr4VyIbX18QDB547UL4D6aIVTc1gwXnSvPwT9bVFUmTdFx9wv6pm","fundingsubtype":"General","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/hubs-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"vFVuFcQXbukQhF6l11abCuxNnu1RGhUtSPyXlZzOXqjb7se31jAaZ4","date":"Aug 2022","amount":"Undisclosed","source":"Tamar Harris Kedar from NGT Healthcare - silent round","eventtype":"FundingRoundEvent","investment":[{"name":"NGT HealthCare II","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ngt-healthcare-ii","logokey":"$4yZ6u06vEQzqZs9uHcW9RvQjln7GhUOcTfznjx5FYKyIR8RLPXgGIV","tagline":null,"urlname":"/investor_page/ngt-healthcare-ii","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkIyLpeMIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"n3SzzNlVTAkgzhbNXDrk64UoMuwkX8c7UJTvltrQCNL4m623KL55oT","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4yZ6u06vEQzqZs9uHcW9RvQjln7GhUOcTfznjx5FYKyIR8RLPXgGIV","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCR0c6QCgw","date":"Jul 2020","amount":"$5M","source":"http://www.ngt3vc.com/elgan-pharma/","eventtype":"FundingRoundEvent","investment":[{"name":"NGT3","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ngt3","logokey":"$mVzRjurw2GNEG1RAxKCn9V9kJVTjhUNAGEzcfgOR9r54qsiEpYn89L","tagline":null,"urlname":"/investor_page/ngt3","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKP27LwKDA","fundingtype":"Incubator","leadpartner":null,"investmentid":"8SsoraNLHb8h4eNc9PlsfjFGTkrUSSGMYFrGhFPKjSgfFJTVJgZW0R","fundingsubtype":"Incubator","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$mVzRjurw2GNEG1RAxKCn9V9kJVTjhUNAGEzcfgOR9r54qsiEpYn89L","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"5/2018","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"ELGAN Pharma","logourl":"https://storage.googleapis.com/clean-finder-353810/$XqBs0ol42LtrlcKm6w8kcc6yIB5l5FIAfbSch3vjeEfTLmEWm0gqNL","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$XqBs0ol42LtrlcKm6w8kcc6yIB5l5FIAfbSch3vjeEfTLmEWm0gqNL","seoabout":"ELGAN Pharma is a clinical-stage neonatology-focused biotechnology company developing safe, tailored therapies to address medical problems and developmenta...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":2,"name":"Nanomaterials","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1upgKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Babies","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If81MwLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA>Nanomaterials#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1upgKDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA>Babies#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If81MwLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|2:>TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA/Nanomaterials#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1upgKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA|2:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA/Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA|3:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA/Babies#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If81MwLDA|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Consumers","key":"0-0","path":"IndustryClassificationModel>Consumers","children":[{"title":"Demographics & Family","key":"0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family","children":[{"title":"Babies","key":"0-0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family>Babies"}]}]},{"title":"Healthcare & Life Sciences","key":"0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-1-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"},{"title":"Providers","key":"0-1-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances","children":[{"title":"Nanomaterials","key":"0-0-0","path":"TechnologyClassificationModel>Materials & Substances>Nanomaterials"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":2,"name":"Nanomaterials","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1upgKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Babies","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If81MwLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Materials & Substances","Nanomaterials"],"targetCustomer":["Consumers","Demographics & Family","Babies","Healthcare & Life Sciences","Healthcare","Patients","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"vFVuFcQXbukQhF6l11abCuxNnu1RGhUtSPyXlZzOXqjb7se31jAaZ4","date":"Aug 2022","amount":"Undisclosed","source":"Tamar Harris Kedar from NGT Healthcare - silent round","eventtype":"FundingRoundEvent","investment":[{"name":"NGT HealthCare II","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ngt-healthcare-ii","logokey":"$4yZ6u06vEQzqZs9uHcW9RvQjln7GhUOcTfznjx5FYKyIR8RLPXgGIV","tagline":null,"urlname":"/investor_page/ngt-healthcare-ii","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkIyLpeMIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"n3SzzNlVTAkgzhbNXDrk64UoMuwkX8c7UJTvltrQCNL4m623KL55oT","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4yZ6u06vEQzqZs9uHcW9RvQjln7GhUOcTfznjx5FYKyIR8RLPXgGIV","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCR0c6QCgw","date":"Jul 2020","amount":"$5M","source":"http://www.ngt3vc.com/elgan-pharma/","eventtype":"FundingRoundEvent","investment":[{"name":"NGT3","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ngt3","logokey":"$mVzRjurw2GNEG1RAxKCn9V9kJVTjhUNAGEzcfgOR9r54qsiEpYn89L","tagline":null,"urlname":"/investor_page/ngt3","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKP27LwKDA","fundingtype":"Incubator","leadpartner":null,"investmentid":"8SsoraNLHb8h4eNc9PlsfjFGTkrUSSGMYFrGhFPKjSgfFJTVJgZW0R","fundingsubtype":"Incubator","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$mVzRjurw2GNEG1RAxKCn9V9kJVTjhUNAGEzcfgOR9r54qsiEpYn89L","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"EiKfAeJyt6OIesxPNxXVkgatvJTMsC10edc9DOb7qDnhL8uyO5itQK","date":"Jul 2023","amount":"$2.5M","source":"https://nocamels.com/2023/07/startup-treating-newborns-in-serious-condition-raises-2-5m/","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"EIC Accelerator","type":"Accelerator","amount":null,"hidden":true,"country":"Belgium","fullurl":"/program_page/eic-accelerator","logokey":null,"tagline":"EIC Accelerator is an accelerator managed by the European Innovation Council and European Commission (EC) based in Brussels, Belgium. The firm seeks to support small and medium enterprises.","urlname":"/program_page/eic-accelerator","isisraeli":0,"investorid":"DSnozIu4tFaENytWcT1Y4Wzro134ttf9vwbDP23n82MplEWezRgvpQ","fundingtype":"General","leadpartner":null,"investmentid":"PZpr4VyIbX18QDB547UL4D6aIVTc1gwXnSvPwT9bVFUmTdFx9wv6pm","fundingsubtype":"General","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/hubs-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}